Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Avacta Group
Avacta Group
Activities:
Research & Development
Analysis
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
CordenPharma & GENEPEP collaborate to leverage peptide drug substance discovery
The partnership has facilitated the expedition of the development, discovery and manufacturing of peptides for early clinical phase
ISPE announces 2024 Facility of the Year Awards category winners
The awards programme recognises pharmaceutical companies that are the 'best' in the industry for innovation, operations, digitalisation, supply chain and social impact
Tabletability, compactability and compressibility: What’s the difference?
To patients and consumers, tablets are a simple and convenient dosage form, but the science behind compressing a block of particles or granules into a single tablet can be...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Research & Development
Avacta achieves milestone in AffyXell joint venture
The second milestone will result in an increase in Avacta’s shareholding in AffyXell, which currently stands at 19%
Research & Development
AffyXell expands partnership with GenScript ProBio
As part of the strategic alliance, GenScript has committed to take an equity position in AffyXell at a future funding round
Finance
Avacta appoints Non-Executive Director to board
Christina Coughlin previously served as CMO to Rubius Therapeutics, where she led the clinical development, translational medicine and regulatory efforts for the company
Analysis
Avacta provides update on its antigen test for Omicron
The company has taken the decision to pause sales of the AffiDX antigen test while it replaces the antibody in the product to ensure its performance with the Omicron variant matches that of the previous mutations
Finance
Astrea Bioseparations invests in infrastructure in UK and Singapore
The company has expanded its R&D facility in Cambridge, UK, and registered a branch office in Singapore
Finance
Avacta appoints Chief Scientific Officer of therapeutics division
Dr Alastair Smith, CEO of Avacta Group, commented: “We are delighted to have Fiona McLaughlin join us as Chief Scientific Officer of our therapeutics division
Finance
Avacta appoints Dr Mark Goldberg as Non-Executive Director
Goldberg currently serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines
Subscribe now